• Explore /
  • Poster
  • / POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC).

POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC).

Abstract Video & Slides Poster

Authors

null

Hyun Kyoo Yoo

AstraZeneca, Cambridge, United Kingdom

Hyun Kyoo Yoo , Hedy L. Kindler , Susan McCutcheon , David McGuinness , Nikunj Patel , Robert Hettle , Rory Goodbody , Seongjung Joo , Gershon Y. Locker , Talia Golan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT02184195

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4626)

DOI

10.1200/JCO.2020.38.15_suppl.4626

Abstract #

4626

Poster Bd #

234

Abstract Disclosures

Similar Posters

First Author: Talia Golan

First Author: Talia Golan

First Author: Kim Anna Reiss

First Author: Vincent Chung